Hepatitis B Virus
Researchers at University of Hong Kong target hepatitis B virus
Published in Hepatitis Weekly, September 28th, 2009
"The aim of this study was to compare the virological and biochemical relapse rates in Asian chronic hepatitis B patients with lamivudine-induced hepatitis B e antigen (HBeAg) seroconversion, between those who stopped therapy after HBeAg seroconversion and those who continued to receive lamivudine. All patients with lamivudine-induced HBeAg seroconversion were included," researchers in Hong Kong, People's Republic of China report.
"who stopped lamivudine after HBeAg seroconversion (n=22) were compared with 79 patients who continued to receive lamivudine (n=79). Demographic, virological, and biochemical parameters were recorded at baseline, and throughout the duration of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2009-09-28)
More Articles from Hepatitis Weekly
- Journal of the National Cancer Institute
Cases of liver cancer reduced in a younger population vaccinated for HBV - Acute Glomerulonephritis
Reports from A. Aggarwal et al highlight recent research in acute glomerulonephritis - Alcoholism
Studies from Seoul National University add new findings in the area of alcoholism - Hepatitis
Research data from Kyushu University update understanding of hepatitis - Hepatitis
Researchers from Drexel University provide details of new studies and findings in the area of hepatitis - Hepatitis B Virus
Report summarizes hepatitis B virus study findings from I.E. Andernach and co-researchers - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
